p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat  by See, Fiona et al.
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P38 Mitogen-Activated Protein Kinase
nhibition Improves Cardiac Function and
ttenuates Left Ventricular Remodeling
ollowing Myocardial Infarction in the Rat
iona See, BSC (HONS),* Walter Thomas PHD,† Kerrie Way, PHD,‡ Alex Tzanidis, PHD,*
ndrew Kompa, PHD,* Dion Lewis,* Silviu Itescu, MBBS (HONS), FRACP,‡
enry Krum, MBBS, PHD, FRACP*
elbourne, Australia
OBJECTIVES The aim of this study was to examine the effect of the p38 mitogen-activated protein kinase
(MAPK) inhibitor, RWJ-67657 (RWJ), on left ventricular (LV) dysfunction and remodeling
post-myocardial infarction (MI) in rats.
BACKGROUND p38 MAPK signaling has been implicated in the progression of chronic heart failure.
METHODS From day 7 post-MI (coronary artery ligation), rats received either RWJ (50 mg/day, by
gavage, n  8, MIRWJ) or vehicle (by gavage, n  8, MIV) for 21 days. Echocardiog-
raphy was performed on day 6, before the commencement of treatment, and on day 27. In
vivo hemodynamic measurements were made on day 28. Sham-operated rats served as
controls.
RESULTS The LV end-diastolic pressure and lung/body weight ratio were reduced, whereas the
maximum rate of rise of LV pressure was increased towards sham levels in MIRWJ
compared with MIV. Baseline echocardiographic studies demonstrated uniform LV
remodeling and dysfunction in MI rats. Fractional shortening (FS) further deteriorated in
MIV, whereas FS was preserved in MIRWJ. Progressive LV dilation and infarct
expansion observed in MIV were inhibited in MIRWJ. MIRWJ also demonstrated
increased myocyte hypertrophy in the peri-infarct and non-infarct zones, and reduced
myocardial collagen and -smooth muscle actin (SMA) immunoreactivity compared with
MIV. The antifibrotic effects of RWJ in vivo may reflect direct effects on cardiac fibroblasts,
because RWJ attenuated transforming growth factor -1–stimulated collagen synthesis and
-SMA expression in isolated cardiac fibroblasts. RWJ also protected cultured myocytes from
hydrogen peroxide-induced apoptosis.
CONCLUSIONS RWJ-67657 treatment post-MI had beneficial effects on LV remodeling and dysfunction,
supporting a key role for p38 MAPK in pathologic cell signaling in these processes and its
inhibition as a novel therapy. (J Am Coll Cardiol 2004;44:1679–89) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.038American College of Cardiology Foundation
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ayocardial infarction (MI) impacts on cardiac output via
oss of functional myocardium at the site of injury. The
onsequences of MI include disturbed loading conditions
ithin the heart, ischemic and oxidative stresses, and
ctivation of various local and systemic neurohormonal
ystems, such as the renin-angiotensin-aldosterone, endo-
helin, and sympathetic nervous systems (1). These alter-
tions to the extracellular environment trigger left ventric-
lar (LV) remodeling characterized by necrosis and
hinning of the infarcted myocardium, LV chamber dila-
ion, fibrosis both at the site of infarct and in the non-
nfarcted myocardium, and hypertrophy of viable myocytes.
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esearch Excellence in Therapeutics, Department of Medicine, Monash University,
lfred Hospital, Melbourne, Australia; †Baker Heart Institute, Melbourne, Australia;
nd ‡Adult Stem Cell Biology and Cardiovascular Disease Group, Department of
edicine, University of Melbourne, Melbourne, Australia. Fiona See is supported by
n NHMRC Dora Lush Biomedical Postgraduate Research Scholarship (Canberra,
ustralia). This study was partially funded by Johnson & Johnson Pharmaceutical
esearch & Development, L.L.C.d
Manuscript received April 19, 2004; revised manuscript received June 23, 2004,
ccepted July 19, 2004.lthough early remodeling may be adaptive and sustain LV
unction in the short term, persistent remodeling may
ontribute to functional decompensation and eventually the
evelopment of the clinical syndrome of heart failure (2).
herefore, identifying the cellular and molecular substrates
nderlying LV remodeling post-MI is an important strategy
n the development of novel therapies to impede heart
ailure disease progression.
Although the extracellular stimuli activated in response to
I may be diverse, there is emerging evidence that these
timuli may converge upon common intracellular pathways
o regulate gene expression and protein function. One such
ntracellular pathway is the p38 mitogen-activated protein
inase (MAPK) signaling cascade. p38 MAPK is activated
n cardiac cells by a range of extracellular stimuli including
schemia (3), hemodynamic stress (4), and neurohormonal
actors such as angiotensin II (AngII) (5), endothelin and
henylephrine (6). In vitro, p38 MAPK may regulate
yocyte apoptosis (7), hypertrophy (8), inflammation (9),
nd fibroblast proliferation (5). These p38 MAPK-
ependent processes characterize the cellular sequelae post-
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p38 MAPK Inhibition Post-MI October 19, 2004:1679–89I, suggesting that p38 MAPK activation may contribute
o progressive LV remodeling post-MI and the transition to
eart failure.
Myocardial p38 MAPK is rapidly activated in rats after
I induced by coronary artery ligation (10). Sustained p38
APK activation in the heart has been associated with LV
emodeling and dysfunction arising from various etiologies
oth in humans (11) and in animal models (12,13). Cardiac
yocyte-specific activation of p38 MAPK in transgenic
ice results in LV remodeling marked by interstitial fibro-
is, myocyte hypertrophy, systolic and diastolic dysfunction,
nd ultimately premature death (12). p38 MAPK activation
s also implicated in hypertensive cardiac hypertrophy and
nd-organ damage in spontaneously hypertensive, stroke-
rone rats maintained on a high-salt/high-fat diet (13).
ong-term pharmacologic blockade of p38 MAPK in these
ats reduced hypertrophy and dysfunction and enhanced
urvival over an 18-week period compared with untreated
nimals. In the failing human heart owing to ischemic
njury, inhibition of p38 MAPK has been shown to improve
x vivo function of ischemic myocardium (14). Together,
he data indicate that p38 MAPK may be a common
athway for LV remodeling and dysfunction, and heart
ailure disease progression arising from diverse etiologic
rigins.
Pharmacologic inhibitors of p38 MAPK have played an
mportant role in investigations of the significance of this
ignaling pathway in disease (3,13,15). RWJ-67657 (RWJ)
s a highly selective inhibitor of the p38- and p38-
APK isoforms (16,17). Similar to other small molecule
nhibitors of p38 MAPK, RWJ contains a pyrindinyl
midazole group, and its mechanism of action is likely to
nvolve blockade of p38 MAPK phosphorylation by up-
tream kinases and/or autophosphorylation via competition
or an adenosine triphosphate binding pocket. The thera-
eutic potential of RWJ in the treatment of cytokine-
ediated inflammatory diseases is currently being investi-
Abbreviations and Acronyms
AngII  angiotensin II
DMEM  Dulbecco’s modified Eagle medium
dP/dtmax  maximum rate of rise of left ventricular
pressure
ERK  extracellular signal regulated protein kinase
FS  fractional shortening
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
MAPK  mitogen-activated protein kinase
MI  myocardial infarction
RWJ  RWJ-67657
SMA  smooth muscle actin
TGF  transforming growth factor
TUNEL  terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick
end labelingated (18–20). Although RWJ has not previously been nvaluated for the treatment of cardiac disease, existing data
n its efficacy, selectivity, and safety in humans and animals
16,17,21) indicate its usefulness as a tool in investigating
he role of p38 MAPK in heart failure disease progression.
Based on these observations, we hypothesized that inhi-
ition of the p38 MAPK signaling cascade would attenuate
V dysfunction and pathologic LV remodeling post-MI.
herefore, we evaluated the effect of RWJ on parameters of
V structure and function after coronary artery ligation in
ats. We also sought to explore potential mechanisms that
ay underlie these effects.
ETHODS
his study was conducted with the approval of the Monash
niversity Alfred Hospital Animal Ethics Committee and
omplied with the “Position of the American Heart Asso-
iation on Research Animal Use,” adopted by the American
eart Association on November 11, 1984.
nimal surgery. Outbred female Sprague-Dawley rats
200 to 220 g, Precinct Animal Centre, Alfred Medical
esearch and Education Project, Melbourne, Australia)
ere anesthetized with isoflurane (3%) and underwent
ither sham surgery or ligation of the left anterior descend-
ng coronary artery to induce MI (22).
reatment. On day 6 after surgery MI animals, which
atisfied electrocardiographic criteria for the presence of an
nterior wall infarct affecting 30% of the LV (23), were
andomized to two treatment groups. One group received
he p38 MAPK inhibitor, RWJ (kind gift of Scott Wads-
orth, PhD, Johnson & Johnson Pharmaceutical Research
Development, L.L.C.), by daily gavage (50 mg/kg/day in
cidified 0.5% methylcellulose; n  8); the second group
eceived an equivalent volume of acidified 0.5% methylcel-
ulose as vehicle control (n 8; Sigma, St. Louis, Missouri).
he dose of RWJ was based on data provided by the
anufacturer, which indicated that oral administration of
his compound at a dose of 50 mg/kg/day to rats for three
eeks inhibited the development of a chronic inflammatory
isease without observable side effects (RWJ-67657 Inves-
igator’s Brochure, Johnson & Johnson Pharmaceutical
esearch & Development, L.L.C.). Sham-operated control
nimals also received vehicle (n  8). Animals were treated
rom day 7 until day 28 post-MI. This delay in the
ommencement of the treatment regimen aimed to inhibit
athologic fibrosis occurring in regions remote from the
nfarct and to avoid interference with early reparative
brosis at the site of infarct. Reparative scar tissue is
stablished within the first week post-MI in rats, whereas
brosis in the regions remote from the infarct begins to
ppear from the second week post-MI (24).
chocardiography. Transthoracic two-dimensional and
-mode echocardiography was performed on days 6 and 27
fter surgery on anesthetized rats using a Sonos 5500
2-MHz probe (Agilent Technologies, Palo Alto, Califor-
ia) (25). Anterior and posterior wall thicknesses and LV
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October 19, 2004:1679–89 p38 MAPK Inhibition Post-MInternal dimensions were measured offline over three con-
ecutive cardiac cycles to calculate LV fractional shortening
FS) (26,27). Infarct size was calculated as a percentage of
he lengths of the epicardial and endocardial circumferences
ccupied by the infarct, measured from two-dimensional
mages (23).
emodynamics and tissue harvesting. On day 27, intra-
ardiac and peripheral hemodynamic parameters were
easured in anesthetized animals (22). Systemic and LV
ressure traces were analyzed using Chart v3.5 (ADInstru-
ents, Castle Hill, NSW, Australia) to derive mean arterial
ressure, diastolic blood pressure, systolic blood pressure,
eft ventricular end-diastolic pressure (LVEDP), and max-
mum rate of rise of LV pressure (dP/dtmax). After
emodynamic measurements, the heart and lungs were
xcised, rinsed in cold 0.9% saline, and weighed. Transverse
ections of the heart were fixed in Tissue-Tek O.C.T.-
mbedding compound (Sakura Finetek, Chuo-ku, Tokyo,
apan) for histology or snap-frozen for subsequent molecu-
ar analyses.
mmunohistochemistry for collagen types I and III in
issue. Using a three-layer immunoperoxidase technique,
araformaldehyde-fixed tissues were stained for collagen
ype I or collagen type III and quantitatively assessed as
reviously described (22).
estern blot analysis of -smooth muscle actin (-SMA).
yocardial tissue protein extracts (20 g) were resolved by
2% sodium dodecyl sulfate-polyacrylamide gel electrophore-
is, then transferred to polyvinylidene fluoride membrane.
embranes were incubated with a monoclonal anti--
MA antibody (1:10,000; Sigma) followed by a horseradish
eroxidase-conjugated rabbit anti-goat immunoglobulin G
Dako, Glostrup, Denmark). Immunoreactive bands were
etected using enhanced chemiluminescence (Amersham,
iscataway, New Jersey).
easurement of myocyte cross-sectional area. The pe-
imeters of 25 myocytes in each of the non-infarcted
yocardium and in the peri-infarct regions in collagen
II-stained sections were traced under 400 magnification
sing computer-based image analysis (ImagePro Plus 3.0,
edia Cybernetics, Silver Spring, Maryland). These data
ere used to calculate the myocyte mean cross-sectional area
n each region of the heart.
eonatal rat cardiac cell cultures. Cardiac cells were
solated from one- to three-day-old neonatal Sprague-
awley rats and cultured as described previously (28).
yocytes were seeded in Dulbecco’s modified Eagle me-
ium (DMEM)/F12 supplemented with 10% horse serum
nd then changed 24 h later to define media, which prevents
he growth of proliferating cells. Fibroblasts were cultured
n DMEM/10% fetal calf serum and used at passages 1 to 3
o ensure relative homogeneity in cell type. After seeding,
broblasts were allowed to adhere overnight, then serum-
eprived for 24 h in DMEM/0.5% bovine serum albumin
upplemented with 0.15 mmol/l ascorbic acid before
reatment. sollagen synthesis by cardiac fibroblasts. Neonatal rat
ardiac fibroblast collagen synthesis stimulated by trans-
orming growth factor (TGF)-1 (4 nmol/l; R&D Systems,
inneapolis, Minnesota) in the presence of RWJ (500
mol/l to 5 mol/l) was estimated by measuring cellular
H-proline incorporation as previously described (29).
ollagen gene expression in cardiac fibroblasts. The
GF-1–stimulated 1(I) and 1(III) procollagen gene
xpression in neonatal rat cardiac fibroblasts cultured in the
resence of RWJ (50 nmol/l) were quantified by Northern
lot analysis (22). Procollagen messenger ribonucleic acid
RNA) levels were standardized to the housekeeping gene,
lyceraldehyde-3-phosphate dehydrogenase to control for
uantitative variability of isolation, transfer, or loading of
otal RNA.
-SMA expression in cardiac fibroblasts. The -SMA
xpression was measured in cardiac fibroblasts cultured in
he presence of RWJ (50 nmol/l) and TGF-1 (4 nmol/l)
y Western blotting as described previously.
yocyte apoptosis. Myocytes were pretreated with RWJ
or 30 min before the addition of 250 mol/l hydrogen
eroxide (H2O2) for 24 h. Deoxyribonucleic acid (DNA)
ragmentation in myocytes was assessed by terminal deoxy-
ucleotidyl transferase-mediated deoxyuridine triphosphate
ick end labeling (TUNEL) using a peroxidase-based
ragEL DNA Fragmentation Detection Kit (Oncogene,
armstadt, Germany) followed by double-staining of myo-
ytes with anti-desmin antibody (1:100; Dako). Cells were
ounted in ten random fields per sample.
electivity of RWJ for p38 MAPK. The effects of RWJ
n the activation of extracellular signal regulated protein
inase (ERK)1/2 and p38 MAPK and hypertrophy in
eonatal rat ventricular myocytes were examined. Myocyte
ultures were infected with an adenovirus coding for the rat
ngiotensin type 1 receptor (MOI 20) for two days (28).
hese cells with then treated with 1 mol/l RWJ for 30 min
efore stimulation with AngII (100 nmol/l). For hypertro-
hy, cells were cultured for an additional 72 h and protein
ontent was determined in cell extracts as previously de-
cribed (28). For determination of MAPK activation, stim-
lation was for 5 min, and cell extracts were resolved on
odium dodecyl sulfate-polyacrylamide gel electrophoresis,
hen Western blotted for activated p38 MAPK (1:2,000
nti-phospho-p38 MAPK; Cell Signaling, Beverly, Massa-
husetts) or ERK (1:2,000 anti-phospho-p44/p42 MAPK;
ell Signaling) and were developed using anti-mouse im-
unoglobulin G-horseradish peroxidase and chemilumi-
escence. Blots were re-probed for total ERK1/2 and p38
APK to confirm equivalent loading.
tatistical analyses. Results are expressed as mean 
EM. All data sets were analyzed by one-way analysis of
ariance (Kruskal-Wallis analysis of variance by ranks)
ollowed by Bonferroni’s post hoc comparisons between
roups. A value of p  0.05 was considered statistically
ignificant.
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emodynamic parameters and organ weights. Vehicle-
reated MI animals demonstrated the characteristic profile
f intracardiac hemodynamic parameters observed post-MI,
ith a two-fold elevation in LVEDP and a 33% reduction
n dP/dtmax compared with shams (p  0.05) (Table 1).
ean arterial pressure tended to be lower in vehicle-treated
I compared with shams, but it was not statistically
ifferent between these two groups. In comparison to
hams, lung weight to body weight ratio and heart weight to
ody weight ratios were increased by 55% and 17%, respec-
ively, in MI rats treated with vehicle (p 0.05). In contrast
o vehicle treatment of MI animals, RWJ treatment resulted
n a significantly lower LVEDP (50%, p  0.05), higher
dP/dtmax (66%, p  0.05), and reduced lung weight to
ody weight ratio (25%, p 0.05). Mean arterial pressure
nd heart weight to body weight ratios were not significantly
ifferent between vehicle-treated and RWJ-treated MI rats.
n a separate study, RWJ had no significant effect on
eripheral and intracardiac hemodynamic parameters in
ham-operated rats compared with vehicle treatment
mean arterial pressure [mm Hg] in shamvehicle vs.
hamRWJ: 129.8  4.6 vs. 126.2  3.4, p  NS;
VEDP [mm Hg]: 2.59  1.3 vs. 3.1  0.7, p  NS;
dP/dtmax[mm Hg ms
1]: 5.8  0.3 vs. 5.8  0.2, p 
S).
chocardiographic data. PRETREATMENT MEASURES. Myo-
ardial infarction rats demonstrated impaired contractile
unction, indicated by a significant 52  1.2% reduction in
S compared with shams (p  0.05) (Table 2). This
mpairment was associated with a large sized infarct (33.7
.4% of the LV circumference) and LV enlargement, with
ncreased LV internal dimensions in both diastole and
ystole compared with shams (diastole: 35.2  2.3%;
ystole: 96.0  5.0%; p  0.05 MIV vs. shams).
mportantly, animals randomized to either the vehicle
reatment or the RWJ treatment groups were well-matched
t baseline, before the commencement of treatment, for LV
ysfunction and dimensions and infarct size (MIV vs.
IRWJ, p  NS).
HANGE AFTER TREATMENT. Whereas FS did not change
able 1. Intracardiac and Peripheral Hemodynamic Parameters
nd Weight Data on Day 28 After Surgery
Sham MIV MIRWJ
VEDP (mm Hg) 9.9  0.9 19.7 3.8* 9.8  1.0†
dP/dtmax (mm Hg ms
1) 7.5  0.5 5.0 1.0* 8.3  0.4†
AP (mm Hg) 87.0  4.3 76.5  12.8 98.0  10.9
W:BW (mg:g) 5.1  0.1 7.9 1.5* 5.9  0.3*†
W:BW (mg:g) 3.6  0.1 4.2 0.2* 4.3  0.1*
ata are represented as mean  SEM. *p  0.05 versus shams. †p  0.05 versus
IV.
HW:BW  heart weight to body weight ratio; LVEDP  left ventricular
nd-diastolic pressure; LW:BW  lung weight to body weight ratio; MAP  mean
rterial pressure; MI  myocardial infarction; dP/dtmax  maximum rate of rise of
eft ventricular pressure; RWJ  RWJ-67657; V  vehicle.n sham-operated rats, contractile function further deterio-
i
vated in MI rats treated with vehicle, indicated by a decrease
n FS (24.2  2.4%) from day 6 to day 27 (Fig. 1a). In
ontrast, MI rats treated with RWJ demonstrated an in-
rease in FS over the treatment period (9.9  3.2%, p 
.05 vs. MIV), resulting in a significantly higher FS
ompared with the vehicle-treated MI group at day 27
Table 3).
Infarct size increased by 17.1  3.0% in vehicle-treated
I rats from day 6 to day 27 (Fig. 1b), resulting in a
ignificantly larger infarct size at the end of the study
ompared with baseline (percent of LV circumference oc-
upied by infarct on day 6: 33.7  0.38% vs. day 27: 39.47
0.24%, p  0.05). In comparison to vehicle treatment,
nfarct expansion was significantly attenuated in MI rats
reated with RWJ, in which infarct size increased by 2.6 
.1% over the treatment period (p  0.05 vs. MIV).
oreover, RWJ-treated MI rats demonstrated significantly
maller infarcts on day 27 compared with MI rats treated
ith vehicle (Table 3) and preservation of infarct size (day
: 35.0  0.46% vs. day 27: 35.92  0.23%, p  NS).
Vehicle-treated MI rats demonstrated LV dilation from
ay 6 to day 27, with increases in both LV internal diastolic
imensions (15.1  3.2%) (Fig. 1c) and LV internal
ystolic dimensions (25.5 4.6%) (Fig. 1d). In contrast to
ehicle-treated MI rats, RWJ-treated MI rats demonstrated
ignificantly less LV dilation (diastole: 6.7  1.7%, p 
.05 vs. MIV; systole: 8.7  2.1%, p  0.05 vs.
IV), so that LV dimensions were not significantly
ifferent on day 6 compared with day 27 in this group (LV
nternal dimensions in diastole [mm] on day 6: 7.5 0.0 vs.
ay 27: 8.0  0.1, p  NS; LV internal dimensions in
ystole [mm] on day 6: 5.7  0.8 vs. day 27: 6.1  0.3, p 
S).
ollagen deposition. In vehicle-treated MI rats, the per-
entage area of myocardium immunopositive for collagen
ype I was increased above sham levels throughout the LV
nfarct (4.6-fold), peri-infarct (3.1-fold), and non-infarct
egions (1.4-fold) (Figs. 2 and 3a). In contrast, treatment
ith RWJ attenuated these increases throughout the LV
infarct: 3.1-fold; peri-infarct: 1.9-fold; non-infarct: 0.04-
old; p 0.05). Collagen type III immunoreactivity was also
ncreased throughout the myocardium after MI but was not
ignificantly affected by RWJ treatment (Figs. 3b and 4).
Consistent with these immunohistochemical data, in-
able 2. Baseline Echocardiographic Parameters Measured
efore the Commencement of Treatment on Day 6
fter Surgery
Sham MIV MIRWJ
ractional shortening (%) 48.7 1.00 23.5  0.63* 21.8 3.2*
nfarct size (%) — 33.7  0.38 35.0  0.46
VIDd (mm) 5.4  0.5 7.3  0.6* 7.5  1.0*
VIDs (mm) 2.8  0.7 5.5  1.0* 5.9  0.8*
ata are presented as mean  SEM. *p  0.05 versus shams.
LVIDd  left ventricular internal diastolic dimensions; LVIDs  left ventricularnternal systolic dimensions; MI  myocardial infarction; RWJ  RWJ-67657; V 
ehicle.
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October 19, 2004:1679–89 p38 MAPK Inhibition Post-MIreases in total myocardial collagen content at 28 days
ost-MI, assessed by tissue hydroxyproline content, tended
o be inhibited in MI animals treated with RWJ in both the
nfarct zone (g/mg tissue sham: 1.49  0.14; MIV:
2.31  1.11; MIRWJ: 14.15  4.15; p  0.05, MIV
s. shams; p  0.08, MIRWJ vs. MIV) and non-infarct
one (sham: 1.58  0.12; MIV: 3.27  0.18; MIRWJ:
.65  0.10; p  0.05, MIV vs. shams; p  0.06,
IRWJ-67657 vs. MIV) (n  4).
-SMA expression. Expression of the myofibroblast
arker, -SMA, was increased 2.2 0.2-fold in the infarct
one and 2.5  0.9-fold in the non-infarct zone compared
ith shams in vehicle-treated MI animals (p  0.05) (Figs.
a and 5b). In contrast, MI animals treated with RWJ
emonstrated significantly less -SMA expression in both
igure 1. Percentage changes in echocardiographic parameters in each grou
ercentage change in infarct size (%) in MI treatment groups. (c) Percenta
hange in LV internal dimensions in systole (LVIDs) (mm). *p 0.05 vers
atched bars  MIRWJ-67657.
able 3. Echocardiographic and Weight Parameters on Day 27
fter Surgery
Sham MIV MIRWJ
ractional shortening (%) 49.4  0.8 17.8 0.7* 24.0  0.9*†
nfarct size (%) — 39.5  0.2 35.9  0.2†
WTd (mm) 1.3  0.2 0.9 0.1* 0.9  0.2*
VIDd (mm) 5.8 0.4 8.4 1.2* 8.0  0.8*†
WTd (mm) 1.3 0.2 1.3 0.3 1.6  0.2
WTs (mm) 2.2 0.1 1.1 0.5* 1.1  0.4*
VIDs (mm) 2.9 0.1 6.9 0.7* 6.1  0.3*†
WTs (mm) 2.1 0.3 2.2 0.4 2.4  0.1
ata are presented as mean  SEM. *p  0.05 versus shams; †p  0.05 versus
IV.
AWTd  anterior wall thickness in diastole; AWTs  anterior wall thickness in
ystole; LVIDd  left ventricular internal diastolic dimensions; LVIDs  left
entricular internal systolic dimensions; MI  myocardial infarction; PWTd b
osterior wall thickness in diastole; PWTs  posterior wall thickness in systole; RWJ
RWJ-67657; V  vehicle.he infarct (1.1  0.3-fold, p  0.05 vs. MIV) and
on-infarct regions (1.7  0.7-fold, p  0.05 vs. MIV).
yocyte size. Myocyte cross-sectional areas in the peri-
nfarct and infarct regions increased in vehicle-treated MI
ats relative to shams by 1.8  0.3-fold and 1.4  0.2-fold,
espectively (p  0.05) (Fig. 6). In MI rats treated with
WJ, this hypertrophic effect was augmented in both the
eri-infarct and the non-infarct regions (p  0.05), indi-
ated by significantly greater relative myocyte cross-
ectional areas in comparison to vehicle-treated MI rats
peri-infarct: 4.1  1.5-fold; non-infarct zone: 1.6 
.2-fold, p  0.05 vs. MIV).
ollagen synthesis by neonatal cardiac fibroblasts in
itro. Neonatal rat cardiac fibroblast collagen synthesis,
stimated by 3H-proline incorporation, was upregulated by
3% in response to TGF-1 stimulation (Fig. 7a). This was
uppressed in a dose-dependent manner by co-treatment of
ells with RWJ (500 pmol/l: 0.9%; 5 nmol/l: 15.5%; 50
mol/l: 21%; 500 nmol/l: 25%; 5 mol/l: 42%; p 
.05 vs. TGF-1 alone). RWJ had no significant effect on
ellular proliferation in the concentration range of 500
mol/l to 50 nmol/l, assessed by 3H-thymidine incorpora-
ion assay under identical conditions to the 3H-proline assay
data not shown). Above this dose range, RWJ had sup-
ressive effects on cellular proliferation. Therefore, a dose of
0 nmol/l RWJ was used in subsequent gene expression
tudies, because this dose inhibited collagen synthesis inde-
endent of effects on cellular proliferation.
The TGF-1 induced a two-fold increase in 1(I)
rocollagen gene expression by neonatal rat cardiac fibro-
r the treatment period. (a) Percentage change in fractional shortening. (b)
nge in LV internal dimensions in diastole (LVIDd) (mm). (d) Percentage
ms. †p 0.05 versus MIV. White bars shams; black barsMIV;p ove
ge chalasts at 24 h in comparison to unstimulated cells (p 0.05)
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p38 MAPK Inhibition Post-MI October 19, 2004:1679–89Fig. 7b). This effect was significantly attenuated by co-
reatment of the cells with 50 nmol/l RWJ (1.2-fold
ncrease over untreated) (p  0.05, vs. untreated). At this
ose, RWJ had no significant effect on basal levels of 1(I)
rocollagen expression.
GF-1–induced -SMA expression in cardiac fibro-
lasts. The TGF-1 stimulation of neonatal rat cardiac
broblasts resulted in a 2.4 0.5-fold induction of -SMA
xpression above levels observed in quiescent cells as as-
essed by Western blot analysis (p 0.05) (Fig. 8). Whereas
WJ had no significant effect on baseline levels of -SMA
xpression (1.1  0.3-fold increase, p  NS vs. unstimu-
ated), the presence of RWJ in culture media significantly
educed -SMA expression stimulated by TGF--1 (1.2 
.1-fold increase, p  0.05 vs. unstimulated).
2O2-induced myocyte apoptosis. H2O2 (250 nmol/l)
nduced a significant increase in the proportion of TUNEL-
ositive cells in culture compared with untreated cells
unstimulated: 0.6  0.4% vs. H2O2: 25  6.7%, p  0.05)
Fig. 9). Although RWJ had no significant effect on basal
evels of apoptosis, RWJ reduced the proportion of H2O2-
nduced TUNEL-positive cells at both concentrations ex-
mined (500 nmol/l: 7.8  2.2%; 1 mol/l: 3.9  1.7%; p
igure 2. Immunolocalization of fibrillar collagen type I by a three-layer im
ollagen type I expression throughout the myocardium (a). In contrast, myo
ncreased deposition of collagen type I in both the non-infarct and peri-i
WJ-67657 demonstrated less collagen type I immunoreactivity in each reg0.05 vs. H2O2 alone). Relectivity of RWJ for p38 MAPK. Angiotensin II stim-
lated a marked increase in phosphorylated p38 MAPK and
RK1/2 in myocytes overexpressing AT1 receptor. Consis-
ent with previous reports characterizing this compound
16), RWJ inhibited p38 MAPK activation independent of
he effects on total p38 MAPK, and with negligible effects
n phosphorylated and total ERK1/2 expression (Fig. 10).
WJ had no significant effect on AngII-induced myocyte
ypertrophy, an effect known to be dependent on ERK1/2
ignaling (data not shown).
ISCUSSION
his is the first study to demonstrate that treatment of rats
rom seven days after MI with RWJ attenuates the natural
rogression of pathologic LV remodeling and dysfunction
ubsequent to MI. Specifically, in comparison to treatment
ith vehicle, treatment of MI rats with RWJ impeded the
evelopment of chronic heart failure (manifested by reduced
ung weight to body weight ratio), preserved LV function
nd dimensions, and inhibited infarct expansion. These
ltrastructural and functional changes were associated with
educed myocardial collagen type I and -SMA expression.
operoxidase technique. Sham-operated animals demonstrated constitutive
um from vehicle-treated myocardial infarction (MI) animals demonstrated
zones (b,d) and in the infarct regions (f). The MI animals treated with
mpared with vehicle-treated MI animals (c, e, g). (Magnification:200.)mun
cardi
nfarctWJ treatment of MI rats augmented myocyte hypertrophy
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October 19, 2004:1679–89 p38 MAPK Inhibition Post-MIn the peri-infarct and non-infarct regions. The antifibrotic
ffects observed in vivo appeared to be attributable to direct
ffects of RWJ on cardiac fibroblasts. In cultured cardiac
broblasts, RWJ suppressed TGF-1–stimulated collagen
ynthesis, 1(I) procollagen gene expression, and expression
f -SMA. Additionally, RWJ protected cultured myocytes
gainst hydrogen peroxide-induced apoptosis. Together,
hese mechanisms may contribute to the preservation of LV
tructure and function observed with RWJ treatment after
I in rats. Given the selectivity of this compound for p38
APK inhibition, demonstrated in myocytes over-
xpressing the AT1 receptor, the findings of this study imply
hat p38 MAPK plays an important role in the progression
f LV remodeling and dysfunction after MI.
38 MAPK-mediated mechanisms of LV remodeling and
ysfunction. Various cellular processes pertinent to LV
emodeling and dysfunction post-MI rely on p38 MAPK
ignaling, including myocyte apoptosis (7), hypertrophy
6,8), and inflammation (9). Whether p38 MAPK plays a
irect role in fibrosis, a hallmark of LV remodeling and
ysfunction post-MI, has not been previously examined. In
he current study, RWJ treatment of MI animals reduced
igure 3. Percentage area of myocardium in the non-infarct zone, peri-
nfarct zone, and infarct zone stained positive for collagen type I (a) and
ollagen type III (b) in each group. Percentage immunoreactivity was
ssessed as a repeat measure in five random fields in each region. Data are
epresented as mean  SEM. n  8. *p  0.05 versus shams. †p  0.05
ersus MIV. White bars  shams; black bars  MIV; hatched bars
MIRWJ-67657.ollagen type I accumulation and -SMA expression chroughout the myocardium. Whereas fibrosis at the site of
nfarct is reparative, excessive deposition of collagen in
egions remote from the infarct is believed to be pathologic.
n particular, the accumulation of collagen type I, which is
haracterized by tensile strength, may contribute to myo-
ardial stiffness by limiting the motion of myocytes, and
ay promote arrhythmias by electrical isolation of adjacent
yocytes (30). Therefore, the inhibitory effect of RWJ on
ollagen type I, in preference to the more elastic collagen
ype III, observed in the present study may provide a
olecular substrate for the beneficial effects on LV structure
nd function observed with RWJ treatment post-MI. The
easons for the differential effects of RWJ on deposition of
ollagen type I versus collagen type III are unclear. Al-
hough collagen types I and III are co-expressed in the
eart, separate control of the respective procollagen genes
ay be possible owing to differences in their promoter
egions, such as the occurrence of positive and negative
egulatory elements (31). However, whether these differ-
nces impact on the binding of transcription factors that
ay be activated by p38 MAPK and thus give rise to
iscrete regulation of collagen I and III expression remains
peculative and awaits comprehensive investigation.
Our in vitro data provide evidence that the antifibrotic
ffects of RWJ treatment post-MI may be independent of
he improvements in hemodynamic status also observed in
his study. RWJ had suppressive effects on TGF-1–
timulated collagen synthesis and 1(I) procollagen gene
xpression in isolated neonatal cardiac fibroblasts. These
ndings are consistent with previous reports demonstrating
hat p38 MAPK may mediate TGF-1–induced collagen
xpression in renal mesangial cells (32,33). Our data further
oint to a potential mechanism for p38 MAPK regulation
f collagen expression by cardiac fibroblasts. The TGF-1
lays a key role in the phenotypic switch of fibroblasts to
yofibroblasts, which express -SMA and demonstrate an
ncreased capacity for extracellular matrix protein synthesis
34). In this study, myocardial -SMA expression was
ound to be increased in vehicle-treated MI rats compared
ith that observed in shams at four weeks post-MI, a time
hen TGF-1 expression is also upregulated (35). In
ontrast to vehicle treatment, RWJ attenuated -SMA
xpression in both the infarct and non-infarct regions. In
ddition, TGF-1 stimulation of -SMA expression in
solated cardiac fibroblasts was inhibited in the presence of
WJ compared with cells treated with TGF-1 alone.
ogether, these findings suggest that p38 MAPK may be
nvolved in TGF-1–induced myofibroblast activation and
ay thus contribute directly to collagen expression and
brosis post-MI.
Compensatory LV hypertrophy in response to injury such
s MI or increased hemodynamic loading conditions may
ustain or even improve cardiac output. In this study, RWJ
reatment of rats post-MI augmented hypertrophy of the
urviving myocytes, indicated by a further increase in myo-
yte cross-sectional area in the peri-infarct and non-infarct
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p38 MAPK Inhibition Post-MI October 19, 2004:1679–89egions, compared with vehicle treatment. This observation
ndicates an antagonistic role for p38 MAPK in myocyte
rowth in the post-MI context, and is consistent with recent
tudies demonstrating that targeted inhibition of p38
APK promotes myocyte hypertrophy (36,37). In contrast,
ehr et al. (13) reported that SB239063, a selective p38
APK inhibitor, attenuated LV hypertrophy in stroke-
rone, spontaneously hypertensive rats fed a high-salt/high-
at diet. A possible explanation for these divergent results is
hat myocyte survival may be differentially regulated by the
38- and p38- isoforms. Whereas myocyte apoptosis and
igure 4. Immunolocalization of fibrillar collagen type III by a three-layer i
ollagen type III expression throughout the myocardium (a). In contrast,
eposition of collagen type III in both the non-infarct and peri-infarct regio
emonstrated similar extents of collagen type III distribution compared w
igure 5. Fold increases in -smooth muscle actin (SMA) expression in
he infarct zone (a) and non-infarcted myocardium (b) compared with
ham-operated hearts. Representative Western blots are shown. n  6 per
roup. *p  0.05 versus shams. †p  0.05 versus MIV. White bars 
hams; black bars  MIV; hatched bars  MIRWJ-67657.
s
Mrowth inhibition are attributable to activation of p38-,
38- activation appears to mediate a survival pathway,
nvolving promotion of myocyte growth and reduction of
poptosis (8). Because RWJ inhibits both p38- and -
soforms (20), the results of the present study may indicate
hat the p38- pathway is preferentially activated in the
operoxidase technique. Sham-operated animals demonstrated constitutive
ardium from myocardial infarction (MI) animals demonstrated increased
,d) and in the infarct region (f). The MI animals treated with RWJ-67657
hicle-treated MI animals (c, e, g). (Magnification: 200).
igure 6. Relative myocyte cross-sectional areas in the non-infarct and
eri-infarct zones compared with shams. n 6 per group. *p 0.05 versusmmun
myoc
ns (bhams. †p  0.05 versus MIV. White bars  shams; black bars 
IV; hatched bars  MIRWJ-67657.
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October 19, 2004:1679–89 p38 MAPK Inhibition Post-MIost-MI setting. Therefore, RWJ treatment post-MI may
nhance myocyte growth as an adaptive response to extra-
ellular stress and thus contribute to the observed improve-
ents in LV function compared with vehicle-treated MI
ats. Because we observed that RWJ had no significant effect
n AngII-induced myocyte growth in vitro, it appears that
lternative stimuli reliant on p38 MAPK signaling may be
nvolved in myocyte hypertrophy post-MI.
RWJ also had a protective effect against apoptosis in
solated myocytes exposed to hydrogen peroxide, which
imics oxidative stress in conditions of ischemia. Consis-
ent with our data, previous studies have shown that p38
APK inhibition reduces apoptosis in cultured myocytes
xposed to oxidative stress (38), whereas p38 MAPK
ownregulation in transgenic mice confers protection
gainst apoptotic death of myocytes induced by ischemia/
eperfusion injury (39). After MI, myocyte apoptosis occurs
oth acutely in the infarcted region and later in regions
emote from the infarct, and has been shown to correlate
ith LV dysfunction (40). Therefore, the inhibitory effects
igure 7. (a) 3H-proline incorporation, an estimate of collagen synthesis,
y neonatal rat cardiac fibroblasts cultured in the presence of TGF-1 and
arious concentrations of RWJ. (b) Northern blot analyses of 1(I)
rocollagen gene expression relative to the housekeeping gene, GAPDH,
n neonatal rat cardiac fibroblasts cultured in the presence of RWJ and
GF-1. n 3 for each condition. Data are represented as mean SEM.
p  0.05 versus unstimulated. †p 0.05 versus TGF-1 stimulation
lone.f RWJ treatment of MI rats on LV dysfunction and
a
0emodeling may derive from its anti-apoptotic actions and
he consequent enhancement of myocyte survival.
It is possible that the beneficial effects of RWJ treatment
n LV function may be independent of the effects on LV
emodeling. For example, specific pharmacologic inhibition
f p38 MAPK activity can reversibly block the negative-
notropic effects of p38 MAPK activation in cultured adult
at cardiomyocytes (41). However, RWJ had no effect on
V function in sham-operated rats, and our in vitro studies
upport a role for p38 MAPK in fibrosis and myocyte
poptosis. Collectively, these data demonstrate that the
ffects of RWJ on LV function are related to direct effects
n post-MI remodeling.
38 MAPK as a therapeutic target post-MI. The results
f this study suggest that inhibition of p38 MAPK is a
romising therapeutic strategy to impede heart failure dis-
ase progression after MI. The anti-remodeling effects of
igure 8. Fold increases in -smooth muscle actin expression compared
ith unstimulated neonatal rat cardiac fibroblasts. n  3 per condition.
ata are from three separate experiments. Representative Western blots are
hown. *p  0.05 versus unstimulated. †p  0.05 versus TGF-1.
igure 9. Myocyte apoptosis induced by hydrogen peroxide assessed by
ercentage of TUNEL-positive myocytes in culture. n 3 per group. Data
re from three separate experiments. *p  0.05 versus unstimulated. †p 
.05 versus TGF-1.
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p38 MAPK Inhibition Post-MI October 19, 2004:1679–89urrent treatments for heart failure, such as angiotensin-
onverting enzyme inhibitors (42) and -blockers (43,44),
re postulated to be key mechanisms underlying improve-
ents in parameters of morbidity and mortality observed
ith such treatments. In the current study, the beneficial
ffects on LV remodeling and dysfunction with p38 MAPK
nhibition post-MI were associated with a decrease in
ung/body weight ratio, a marker of “clinical” chronic heart
ailure. However, larger and longer-term studies are re-
uired to determine whether these benefits of p38 MAPK
nhibition post-MI translate into enhanced survival.
tudy limitations. Whereas there is strong evidence dem-
nstrating the potency of RWJ against p38 MAPK (16,17),
t high concentrations the compound also possesses inhib-
tory activities against other kinases, such as c-src, p56 lck,
nd ERK-2 (17). Non-specific activity has also been re-
orted for other p38 MAPK inhibitors (45,46). However, it
s important to note that the potency of such non-specific
nhibitory actions of RWJ is relatively small compared with
ts actions against p38 MAPK. For example, it is 20-fold
ess potent for inhibition of JNK2 compared with p38-
personal communication, Scott Wadsworth, PhD, Johnson
Johnson Pharmaceutical Research & Development,
.L.C., February 22, 2004). Therefore, despite the possi-
ility of non-specific inhibition of other kinases by RWJ,
he observations reported in this study are likely to be
rimarily attributable to p38 MAPK inhibition.
onclusion. In conclusion, the results of the present study
emonstrate that treatment with a p38 MAPK inhibitor,
igure 10. (Top panel) Representative Western blots for phosphorylated
nd total p38 MAPK expression and (bottom panel) phosphorylated and
otal ERK1/2 expression in neonatal rat cardiac myocytes infected with an
denovirus coding for the rat angiotensin type I receptor. AngII 
ngiotensin II; RWJ  RWJ-67657.WJ, from seven days after MI attenuated pathologicardiac remodeling and LV dysfunction. The findings of the
resent study therefore suggest that the p38 MAPK signal-
ng cascade may be an important pathway in the progression
f LV dysfunction and pathologic remodeling after MI.
urthermore, p38 MAPK inhibition may be a useful treat-
ent strategy in impeding heart failure disease progression.
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